S-Biomedic, an early stage biotech company focused on skin microbiome, has secured financing enabling the company to advance its lead product for acne patients.
Beerse, Belgium, February 9th 2017. S-Biomedic has developed a method to directly modulate the skin microbiome, with applications in dermatology and the cosmetic industry. The skin microbiome, a habitat of billions of good and bad bacteria, contributes to conditions ranging from acne, eczema and rosacea to ageing. The company was founded by Veronika Oudova, Bernhard Pätzold and Marc Güell and is located at the JLINX facilities in Beerse, Belgium.
The financing is led by Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and supported by CG Health Ventures. S-Biomedic will conduct clinical trials to provide proof of concept for their lead product for acne patients and expand their technology platform to generate products for other skin conditions.
S-Biomedic is amongst the first companies joining Johnson & Johnson Innovation, JLINX, managed and supported by Bioqube Ventures and is leveraging the full potential of this new investment and incubation model: venture financing by JJDC, access to skin care expertise through Johnson & Johnson Consumer Inc. and access to the capabilities at the Janssen Research & Development site in Beerse, Belgium.
Co-founder and CEO Veronika Oudova states: “It is an exciting step for S-Biomedic to be able to access the resources of such an experienced player in the field. I believe we can learn a great deal being part of this new incubation model and it will help us accelerate the development of our technology and our first products.”